Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.

被引：17
|
作者：
Shapiro, G.
LoRusso, P.
Kwak, E. L.
Cleary, J. M.
Musib, L.
Jones, C.
de Crespigny, A.
Belvin, M.
McKenzie, M.
Gates, M. R.
Chan, I. T.
Bendell, J. C.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Karmanos Canc Inst, Detroit, MI USA
[3] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3005
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors
    Bendell, Johanna
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Musib, Luna
    Jones, Cheryl
    De Crespigny, Alex
    Belvin, Marcia
    McKenzie, Meghan
    Gates, Mary R.
    Chan, Iris
    Shapiro, Geoffrey
    CANCER RESEARCH, 2011, 71
  • [2] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Geoffrey I. Shapiro
    Patricia LoRusso
    Eunice Kwak
    Susan Pandya
    Charles M. Rudin
    Carla Kurkjian
    James M. Cleary
    Mary Jo Pilat
    Suzanne Jones
    Alex de Crespigny
    Jill Fredrickson
    Luna Musib
    Yibing Yan
    Matthew Wongchenko
    Hsin-Ju Hsieh
    Mary R. Gates
    Iris T. Chan
    Johanna Bendell
    Investigational New Drugs, 2020, 38 : 419 - 432
  • [3] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Shapiro, Geoffrey, I
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Rudin, Charles M.
    Kurkjian, Carla
    Cleary, James M.
    Pilat, Mary Jo
    Jones, Suzanne
    de Crespigny, Alex
    Fredrickson, Jill
    Musib, Luna
    Yan, Yibing
    Wongchenko, Matthew
    Hsieh, Hsin-Ju
    Gates, Mary R.
    Chan, Iris T.
    Bendell, Johanna
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 419 - 432
  • [4] A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.
    LoRusso, Patricia
    Shapiro, Geoffrey
    Pandya, Shuchi Sumant
    Kwak, Eunice Lee
    Jones, Cheryl
    Belvin, Marcia
    Musib, Luna C.
    de Crespigny, Alex
    McKenzie, Meghan
    Gates, Mary R.
    Chan, Iris Tan-Chi
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
    Hoeflich, Klaus P.
    Merchant, Mark
    Orr, Christine
    Chan, Jocelyn
    Den Otter, Doug
    Berry, Leanne
    Kasman, Ian
    Koeppen, Hartmut
    Rice, Ken
    Yang, Nai-Ying
    Engst, Stefan
    Johnston, Stuart
    Friedman, Lori S.
    Belvin, Marcia
    CANCER RESEARCH, 2012, 72 (01) : 210 - 219
  • [6] Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumor growth inhibition in vivo
    Belvin, M.
    Berry, L.
    Chan, J.
    den Otter, D.
    Friedman, L.
    Hoeflich, K.
    Koeppen, H.
    Merchant, M.
    Orr, C.
    Rice, K.
    EJC SUPPLEMENTS, 2010, 8 (07): : 48 - 48
  • [7] PK-PD Modeling of Combination Efficacy Effect from Administration of a MEK Inhibitor, GDC-0973 and PI3K Inhibitor, GDC-0941 in A2058 Xenografts
    Choo, Edna F.
    Belvin, Marcia
    Hoeflich, Klaus
    Merchant, Mark
    Otter, Douglas Dan
    Salphati, Laurent
    DRUG METABOLISM REVIEWS, 2010, 42 : 268 - 268
  • [8] PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts
    Choo, Edna F.
    Ng, Chee M.
    Berry, Leanne
    Belvin, Marcia
    Lewin-Koh, Nicholas
    Merchant, Mark
    Salphati, Laurent
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 133 - 143
  • [9] PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts
    Edna F. Choo
    Chee M. Ng
    Leanne Berry
    Marcia Belvin
    Nicholas Lewin-Koh
    Mark Merchant
    Laurent Salphati
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 133 - 143
  • [10] A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors
    Rosen, Lee
    LoRusso, Patricia
    Ma, Wen Wee
    Goldman, Johathan
    Weise, Amy
    Colevas, A. Dimitrios
    Adjei, Alex
    Yazji, Salim
    Shen, Angela
    Johnston, Stuart
    Gates, Mary R.
    Jones, Cheryl
    Musib, Luna
    De Crespigny, Alex
    Chan, Iris
    Sikic, Branimir
    CANCER RESEARCH, 2011, 71
12345